Evogene (NASDAQ: EVGN) reported Q1 EPS of ($0.15), $0.02 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $640 thousand versus the consensus estimate of $590 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.